Gene, Stem Cell, and Alternative Therapies for SCA 1

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2016 Aug 30

PMID 27570504

Citations 9

Authors

Jacob L Wagner

Deirdre M OConnor

Anthony Donsante

Nicholas M Boulis

Affiliations

Soon will be listed here.

Abstract

Spinocerebellar ataxia 1 is an autosomal dominant disease characterized by neurodegeneration and motor dysfunction. In disease pathogenesis, polyglutamine expansion within Ataxin-1, a gene involved in transcriptional repression, causes protein nuclear inclusions to form. Most notably, neuronal dysfunction presents in Purkinje cells. However, the effect of mutant Ataxin-1 is not entirely understood. Two mouse models are employed to represent spinocerebellar ataxia 1, a B05 transgenic model that specifically expresses mutant Ataxin-1 in Purkinje cells, and a Sca1 154Q/2Q model that inserts the polyglutamine expansion into the mouse Ataxin-1 locus so that the mutant Ataxin-1 is expressed in all cells that express Ataxin-1. This review aims to summarize and evaluate the wide variety of therapies proposed for spinocerebellar ataxia 1, specifically gene and stem cell therapies.

Citing Articles

Advancing life: innovative approaches to enhance survival in sickle cell anemia patients.

Obeagu E, Adias T, Obeagu G Ann Med Surg (Lond). 2024; 86(10):6021-6036.

PMID: 39359845 PMC: 11444627. DOI: 10.1097/MS9.0000000000002534.

Spastic paraplegia is the main manifestation of a spinocerebellar ataxia type 8 lineage in China: a case report and review of literature.

Chen S, Li S, Liu Y, She R, Jiang W Front Hum Neurosci. 2023; 17:1198309.

PMID: 37529405 PMC: 10388100. DOI: 10.3389/fnhum.2023.1198309.

Therapeutic Strategies for Spinocerebellar Ataxia Type 1.

Kerkhof L, van de Warrenburg B, van Roon-Mom W, Buijsen R Biomolecules. 2023; 13(5).

PMID: 37238658 PMC: 10216181. DOI: 10.3390/biom13050788.

On the identification of potential novel therapeutic targets for spinocerebellar ataxia type 1 (SCA1) neurodegenerative disease using EvoPPI3.

Sousa A, Rocha S, Vieira J, Reboiro-Jato M, Lopez-Fernandez H, Vieira C J Integr Bioinform. 2023; 20(2).

PMID: 36848492 PMC: 10561075. DOI: 10.1515/jib-2022-0056.

Cognitive Decline and Mood Alterations in the Mouse Model of Spinocerebellar Ataxia Type 2.

Marinina K, Bezprozvanny I, Egorova P Cerebellum. 2023; 23(1):145-161.

PMID: 36680704 DOI: 10.1007/s12311-023-01520-w.

References

Goold R, Hubank M, Hunt A, Holton J, Menon R, Revesz T . Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet. 2007; 16(17):2122-34. DOI: 10.1093/hmg/ddm162. View

Matilla T, Volpini V, Genis D, Rosell J, Corral J, Davalos A . Presymptomatic analysis of spinocerebellar ataxia type 1 (SCA1) via the expansion of the SCA1 CAG-repeat in a large pedigree displaying anticipation and parental male bias. Hum Mol Genet. 1993; 2(12):2123-8. DOI: 10.1093/hmg/2.12.2123. View

Xia H, Mao Q, Paulson H, Davidson B . siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol. 2002; 20(10):1006-10. DOI: 10.1038/nbt739. View

Alvarez-Dolado M, Pardal R, Garcia-Verdugo J, Fike J, Lee H, Pfeffer K . Fusion of bone-marrow-derived cells with Purkinje neurons, cardiomyocytes and hepatocytes. Nature. 2003; 425(6961):968-73. DOI: 10.1038/nature02069. View

Burright E, Clark H, Servadio A, Matilla T, Feddersen R, Yunis W . SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell. 1995; 82(6):937-48. DOI: 10.1016/0092-8674(95)90273-2. View

Cummings C, Mancini M, Antalffy B, DeFranco D, Orr H, Zoghbi H . Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet. 1998; 19(2):148-54. DOI: 10.1038/502. View

Kang S, Jaworski A, Ohshima K, Wells R . Expansion and deletion of CTG repeats from human disease genes are determined by the direction of replication in E. coli. Nat Genet. 1995; 10(2):213-8. DOI: 10.1038/ng0695-213. View

Kang S, Hong S . Molecular pathogenesis of spinocerebellar ataxia type 1 disease. Mol Cells. 2009; 27(6):621-7. DOI: 10.1007/s10059-009-0095-y. View

Hong S, Ka S, Kim S, Park Y, Kang S . p80 coilin, a coiled body-specific protein, interacts with ataxin-1, the SCA1 gene product. Biochim Biophys Acta. 2003; 1638(1):35-42. DOI: 10.1016/s0925-4439(03)00038-3. View

10.

Kaut O, Jacobi H, Coch C, Prochnicki A, Minnerop M, Klockgether T . A randomized pilot study of stochastic vibration therapy in spinocerebellar ataxia. Cerebellum. 2013; 13(2):237-42. DOI: 10.1007/s12311-013-0532-5. View

11.

Hearst S, Shao Q, Lopez M, Raucher D, Vig P . Focused cerebellar laser light induced hyperthermia improves symptoms and pathology of polyglutamine disease SCA1 in a mouse model. Cerebellum. 2014; 13(5):596-606. DOI: 10.1007/s12311-014-0576-1. View

12.

Genis D, Matilla T, Volpini V, Rosell J, Davalos A, Ferrer I . Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred: (CAG)n expansion and early premonitory signs and symptoms. Neurology. 1995; 45(1):24-30. DOI: 10.1212/wnl.45.1.24. View

13.

Jorgensen N, Andresen J, Lagalwar S, Armstrong B, Stevens S, Byam C . Phosphorylation of ATXN1 at Ser776 in the cerebellum. J Neurochem. 2009; 110(2):675-86. PMC: 2754139. DOI: 10.1111/j.1471-4159.2009.06164.x. View

14.

Watase K, Gatchel J, Sun Y, Emamian E, Atkinson R, Richman R . Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007; 4(5):e182. PMC: 1880853. DOI: 10.1371/journal.pmed.0040182. View

15.

Harper S, Staber P, He X, Eliason S, Martins I, Mao Q . RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc Natl Acad Sci U S A. 2005; 102(16):5820-5. PMC: 556303. DOI: 10.1073/pnas.0501507102. View

16.

Glass C, Saijo K, Winner B, Marchetto M, Gage F . Mechanisms underlying inflammation in neurodegeneration. Cell. 2010; 140(6):918-34. PMC: 2873093. DOI: 10.1016/j.cell.2010.02.016. View

17.

Vandaele S, Nordquist D, Feddersen R, Tretjakoff I, Peterson A, Orr H . Purkinje cell protein-2 regulatory regions and transgene expression in cerebellar compartments. Genes Dev. 1991; 5(7):1136-48. DOI: 10.1101/gad.5.7.1136. View

18.

Jones J, Jaramillo-Merchan J, Bueno C, Pastor D, Viso-Leon M, Martinez S . Mesenchymal stem cells rescue Purkinje cells and improve motor functions in a mouse model of cerebellar ataxia. Neurobiol Dis. 2010; 40(2):415-23. DOI: 10.1016/j.nbd.2010.07.001. View

19.

Lam Y, Bowman A, Jafar-Nejad P, Lim J, Richman R, Fryer J . ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell. 2006; 127(7):1335-47. DOI: 10.1016/j.cell.2006.11.038. View

20.

Yue S, Serra H, Zoghbi H, Orr H . The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract. Hum Mol Genet. 2001; 10(1):25-30. DOI: 10.1093/hmg/10.1.25. View